Q2 EPS Estimate for Century Therapeutics Lowered by Analyst

Century Therapeutics, Inc. (NASDAQ:IPSC) – Equities research analysts at Leerink Partnrs reduced their Q2 2025 earnings per share (EPS) estimates for shares of Century Therapeutics in a research report issued on Monday, May 19th. Leerink Partnrs analyst D. Graybosch now forecasts that the company will post earnings of ($0.37) per share for the quarter, down from their previous forecast of ($0.14). The consensus estimate for Century Therapeutics’ current full-year earnings is ($1.61) per share. Leerink Partnrs also issued estimates for Century Therapeutics’ Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.32) EPS, FY2025 earnings at ($0.13) EPS, Q1 2026 earnings at ($0.32) EPS, Q2 2026 earnings at ($0.28) EPS, Q3 2026 earnings at ($0.33) EPS, Q4 2026 earnings at ($1.27) EPS, FY2026 earnings at ($1.27) EPS, FY2027 earnings at ($1.25) EPS, FY2028 earnings at ($0.98) EPS and FY2029 earnings at ($0.87) EPS.

Century Therapeutics (NASDAQ:IPSC) last issued its quarterly earnings data on Thursday, May 15th. The company reported $0.89 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $1.20. The business had revenue of $109.16 million during the quarter, compared to analysts’ expectations of $45.52 million. Century Therapeutics had a negative return on equity of 61.66% and a negative net margin of 4,837.73%.

Several other brokerages have also weighed in on IPSC. Piper Sandler cut their price target on Century Therapeutics from $4.00 to $2.00 and set an “overweight” rating for the company in a research note on Thursday, March 20th. Guggenheim restated a “buy” rating on shares of Century Therapeutics in a research note on Friday, March 28th. HC Wainwright cut their price target on Century Therapeutics from $5.00 to $2.00 and set a “buy” rating for the company in a research note on Thursday, April 3rd. Finally, Chardan Capital cut their price target on Century Therapeutics from $7.00 to $6.00 and set a “buy” rating for the company in a research note on Friday, May 16th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $4.20.

Century Therapeutics Stock Up 8.2%

Shares of Century Therapeutics stock opened at $0.60 on Wednesday. Century Therapeutics has a twelve month low of $0.34 and a twelve month high of $3.47. The business has a 50-day moving average price of $0.52 and a 200 day moving average price of $0.85. The firm has a market cap of $51.70 million, a PE ratio of -0.32 and a beta of 1.80.

Institutional Investors Weigh In On Century Therapeutics

Several large investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. increased its stake in Century Therapeutics by 26.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 179,635 shares of the company’s stock worth $86,000 after buying an additional 38,052 shares in the last quarter. AQR Capital Management LLC increased its stake in Century Therapeutics by 358.9% during the 1st quarter. AQR Capital Management LLC now owns 111,079 shares of the company’s stock worth $53,000 after buying an additional 86,875 shares in the last quarter. Nuveen LLC purchased a new stake in Century Therapeutics during the 1st quarter worth approximately $75,000. Squarepoint Ops LLC increased its stake in Century Therapeutics by 56.0% during the 4th quarter. Squarepoint Ops LLC now owns 164,871 shares of the company’s stock worth $167,000 after buying an additional 59,174 shares in the last quarter. Finally, Two Sigma Investments LP purchased a new stake in Century Therapeutics during the 4th quarter worth approximately $67,000. 50.20% of the stock is currently owned by hedge funds and other institutional investors.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.